

What if you were surrounded by the brightest ideas?

Year in Review Breast Cancer is an idea cultivated to make you part of the best breast cancer science from year 2021. This meeting drives unbiased discussion, ask bold questions and helps you re-define what is possible to practice Monday morning. We continue to filter and bring out the brightest of publications on table for thoughtful discussion. Keeping in mind the Indian context, YIR thrives to make the scientific program inclusive and one that impacts practice for optimized patients care.

Register today. Change life of your patients

Academic Organizing Partners



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Monday, 10th January, 2022

Tuesday, 11th January, 2022

Wednesday, 12th January, 2022

Thursday, 13th January, 2022

Friday, 14th January, 2022

Saturday, 15th January, 2022

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

10th - 15th JAN 2022

Dear Colleagues,

Women's Cancer Initiative - Tata Memorial Hospital and Nag Foundation invite you for the **"7th Edition of Year in Review: Breast Cancer Conference"**. This conference will be held virtually from **10th Jan to 15th Jan 2022** and presentations will be released at 9.00am daily and you can watch them throughout the day at your leisure. Keynote presentation and panel discussions will be live on Saturday from 4.00pm to 9.00pm

The scientific program of the Year In Review stems from data presented at major breast cancer meetings and noteworthy publications from peer reviewed journals, likely to make an impact on our daily clinical practice.

The popularity of the Year In Review Breast Cancer relies on an unbiased selection of high quality research which is presented in an interactive form and discussed in the Indian context. A wide range of topics is reviewed ranging from Translational science to Supportive care. This aims to give participants clear visibility on how they can apply this information to their immediate practice, as well as keeping in mind the potential of new research.

This virtual meeting take place over 6 days and will be broadly classified in the following sessions:

- Monday : Loco-regional therapies in breast cancer
- Tuesday : HR+ve Breast Cancer
- Wednesday : HER2+ve Breast Cancer
- Thursday : Triple -ve Breast Cancer
- Friday : Translational science & Supportive care
- Saturday : Keynote presentations and panel discussions

YIR has become an important annual meeting in India for breast cancer. We have been going strong since 2016 with your active participation. We request you to circulate this flyer amongst your colleagues and students.

We look forward to your participation in YIR 2022.

With best wishes,

Organizing Chairperson

Dr. Sudeep Gupta
Director, ACTREC,
Professor of Medical Oncology,
Tata Memorial Centre, Mumbai
sudeepgupta04@yahoo.com

Dr. Shona Nag
Director of Oncology,
Sahyadri Hospital,
Pune
shonanag3@gmail.com

Click on the link to register
<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

10th - 15th JAN 2022

Highlights of the Meeting

- » Select publications shortlisted from 30+ journals
- » Selected abstracts for major cancer conferences
- » State of the art keynote talks
- » Meet National experts
- » Extended rapid review session

Session Classification

- » 10th Jan, Monday : Loco-Regional therapies in breast cancer
- » 11th Jan, Tuesday : HR+ve Breast Cancer
- » 12th Jan, Wednesday : HER2+ve Breast Cancer
- » 13th Jan, Thursday : Triple -ve Breast Cancer
- » 14th Jan, Friday : Translational Science & Supportive Care
- » 15th Jan, Saturday : Keynote Presentations and Panel Discussions



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

10th - 15th JAN 2022

International Speaker



Dr. Shaheenah Dawood

President, UAE Cancer Congress
Co-President, Asia Pacific Breast Cancer Summit (ABCS)
Head, Consultant Medical Oncologist,
Mediclinic Parkview Hospital, Dubai

Dr. Dawood is an extremely experienced oncologist. She graduated from Dubai Medical College in 1998 and undertook further training within Dubai Health Authority before attaining a Medical Oncology fellowship from McGill University, Montreal, Canada, and the Susan Komen Breast Cancer fellowship from the University of Texas M.D. Anderson Cancer Center, Houston, USA. She attained her Master of Public Health from the Harvard School of Public Health in 2008 and has over 100 papers to her credit including 34 peer review original articles, 15 review articles and nine book chapters. She is also an Editorial fellow of the New England Journal of Medicine and serves as a reviewer for multiple journals including the Journal of Clinical Oncology. She currently serves as president of the UAE Cancer Congress that is held annually in Dubai and is Co-President of the Asia Pacific Breast Cancer Summit (ABCS).

Click on the link to register
<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]
Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

10th - 15th JAN 2022

International Speaker



Dr. Nadia Harbeck

Head, Breast Center,
Dept. of OB& GYN,
University of Munich, Germany

Dr. Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB & GYN, University of Munich (LMU), Germany. She obtained her specialist degree (OB & GYN) at the Technical University of Munich (TUM) and her medical degree from the University of Munich. From 2005-2009, she was an assistant professor and head of Conservative Senology at TUM and from 2009-2011, she was head of the Breast Center at the University of Cologne, Germany.

Professor Harbeck is a member of the expert panel issuing the yearly updated evidence-based AGO Guidelines for breast cancer therapy in Germany (www.ago-online.de). She is scientific director of the West German Study Group (www.wsg-online.com). From 2009-2015, she served on the executive board of the EORTC as the chair of the translational research division. Professor Harbeck is principal investigator or steering committee member of numerous breast cancer trials, particularly with novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumours. She has a strong interest in eHealth and is a co-developer of CANKADO, an international digital patient diary (www.cankado.com).

Professor Harbeck has authored more than 480 papers in peer-reviewed journals (h-index 82) and is coordinating editor-in-chief of Breast Care (Karger Publishers). She is a panel member of several international breast cancer consensus conferences, such as for advanced breast cancer (ABC), breast cancer in young women (BCY), and early breast cancer (St. Gallen).

In 2020, Professor Harbeck received the 2020 ESMO Lifetime Achievement Award. She has also numerous other recognitions of her clinical and translational research such as the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award (Emmanuel van der Schueren Lecture), the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest ranking abstract.

Click on the link to register
<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

10th - 15th JAN 2022

International Speaker



Dr. Giuseppe Curigliano

Associate Professor, Dept. of Medical Oncology,
University of Milan & Head,
Division of Early Drug Development,
European Institute of Oncology, IRCCS, Italy

Dr. Giuseppe Curigliano, MD PhD, is Associate Professor of Medical Oncology at the University of Milano and the Head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, Italy. He is a clinician and researcher specialising in early drug development for patients with solid tumours with a special commitment to breast cancer. He has been a member of the Italian National Health Council since 2018 and, in 2019, he served as Chair of the Scientific Committee of The Lega Nazionale Lotta ai Tumori. He has served as a Member of the ESMO Breast Cancer Faculty since 2001 and he is currently the Faculty Coordinator. He has also served on the Scientific Committee for the St Gallen Conference since 2011, and was the Scientific Co-Chair in St Gallen 2017 and 2019.

He has been an Editorial Board Member for Annals of Oncology since 2014, and serves as Co-Editor in Chief of The Breast, Co-Editor in Chief of Cancer Treatment Reviews, Associate Editor of the European Journal of Cancer, Editor of the Journal of Clinical Oncology. He also serves on the European School of Oncology (ESO) faculty committee.

Dr. Curigliano serves ESMO as the Chair of the Guidelines Committee and is a Council Member. He is also the Chair of the Nomination Committee. Since 2016 he has served in the ESMO Women for Oncology Committee, the ESMO Membership Committee, the ESMO Press and Media Affairs Committee, the ESMO Global Policy Committee and the ESMO Translational Research Working Group.

He served as the Scientific Chair of the IMPAKT ESMO meeting that was held in Brussels in 2014 and as the Breast Cancer (metastatic) Track Chair of the ESMO 2014 meeting in Madrid. He served as Scientific Co-Chair of the ESMO Breast Cancer Congress in 2019 and 2020.

He was awarded with the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017.

He has contributed to over 390 peer-reviewed publications.

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

10th - 15th JAN 2022

International Speaker



Dr. Aditya Bardia

Assistant Professor, Medicine, Harvard Medical School
Attending Physician, Medical Oncology,
Massachusetts General Hospital,
Boston, USA

Dr. Bardia is interested in developing successful targeted and personalized therapies to improve the outcomes of patients and families afflicted with breast cancer. The accurate identification of target is crucial for success of targeted therapies, and Dr. Bardia is involved in the clinical development of tumor genotyping as well as circulating tumor cells (CTCs) to facilitate accurate diagnosis, therapy selection, and real-time monitoring of breast cancer. In collaboration the CTC center and Haber lab, his research on molecular changes in CTCs in metastatic breast cancer has elucidated the role of epithelial-mesenchymal transition, and provided proof-of-principle that ex-vivo CTC culture and molecular drug testing is feasible in breast cancer. Dr. Bardia is the principal investigator of clinical trials investigating the role of targeted therapy combinations, including novel ER agents and CDK 4/6 inhibitors, for patients with breast cancer. Dr. Bardia is the recipient of Young Investigator Award from the ASCO Conquer Cancer Foundation and Career Catalyst Award for Susan K Komen Foundation. Dr. Bardia is on the editorial board of ASCO University and faculty member of molecular tumor board by ASCO University.

Click on the link to register
<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



10th - 15th JAN 2022

International Speaker



Prof. Soo Chin Lee

Professor and Senior Principal Investigator,
Cancer Science Institute of Singapore, NUS
Head and Senior Consultant, Dept. of Hematology/Oncology,
National University of Singapore

Professor Lee Soo Chin's laboratory is focused on developing novel therapeutics and predictive biomarkers in breast cancer, with additional interest in pharmacogenetics and inter-ethnic differences. She and her team have studied several novel therapeutic strategies in breast cancer, including using low dose, short-course sunitinib to normalize tumor vasculature to improve chemotherapy delivery into tumor, combining lenvatinib, a RET inhibitor, with letrozole, to overcome endocrine resistance in hormone receptor positive breast cancer, and using expanded activated natural killer cells to augment antibody-directed cell cytotoxicity induced by trastuzumab in HER2+ breast cancer. She and her collaborators found chromosome 1q21.3 amplification to be a trackable biomarker that can be detected on liquid biopsy for breast cancer recurrence. An actionable target, IRAK1, was identified in the amplification region, and her team is currently conducting a clinical trial of pacritinib, an IRAK1 inhibitor, using cell-free DNA detection of 1q21.3 amplification as a biomarker to select cancer patients for treatment. In the field of pharmacogenetics, Professor Lee's team is studying the UGT2B17 null variant, which is common in Asians but rare in Caucasians, in relation to the pharmacokinetics and pharmacodynamics of exemestane, a commonly used endocrine therapy in hormone receptor positive breast cancer patients. Strong correlation was observed between UGT2B17 genotype and exemestane pharmacokinetics, highlighting that inter-ethnic differences in genetic make-up could account for geographic differences in outcomes to anti-cancer treatment.

Click on the link to register
<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 1 - Monday 10th January, 2022

Scientific Program

Session 1 : Loco-Regional therapies in breast cancer


6:30 - 6:35 pm

Welcome Address: Dr. Shona Nag

6:35 - 6:45 pm


 Chairpersons: Dr. Sanjay Deshmukh, Dr. Shekhar Salkar

 Speaker: Dr. V. Sridevi

 Advanced Breast Cancer (LABC): Real-World outcome of patients from Cancer Institute, Chennai

Author: Velusamy Sridevi

Citation: JCO Global Oncol 7:767-781


 Frequency and outcomes of new suspicious lesions on Breast MRI in the setting of neoadjuvant therapy

Author: Donna A Eckstein

Citation: AJR Am J Roentgenol. 2021 Mar;216(3):633-639


6:45 - 6:55 pm

 Speaker: Dr. Pragnya Chigurupati

 Patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA, GBG75, ABCSG43): Persistent impact of axillary surgery on arm and breast symptoms in early breast cancer

Author: Gerber B

Citation: SABCS 2021# GS4-03

 Preservation of axillary lymph nodes compared to complete dissection in T1-T2 breast cancer patients presenting 1-2 metastatic sentinel lymph nodes. A multicenter randomized clinical trial. Sinodar One

Author: Gentile D

Citation: SABCS 2021 #GS4-05

Click on the link to register

<https://www.riveroute.in/yir2022>

Scientific Event Partner

riveroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 1 - Monday 10th January, 2022


Scientific Program

Session 1 : Loco-Regional therapies in breast cancer

6:55 - 7:05 pm


 Chairpersons: Dr. Suchanda Goswami, Dr. Namita Pandey

 Speaker: Dr. Sanjay M H

 Acute toxicity associated with a 3-week versus a standard 5-week regimen for loco regional breast radiotherapy delivered in the UNICANCER HypoG-01 phase III trial

Author: RIVERA ET AL


Citation: ESMO 2021 #121MO


 Effect of Elective Internal Mammary Node Irradiation on Disease-Free survival in women with Node-Positive Breast Cancer: A Randomized phase 3 clinical trial

Author: Kim YB

Citation: JAMA Oncol. Published online October 25, 2021


7:05 - 7:15 pm

 Speaker: Dr. Manjula Rao

 Nodal Recurrence in patients with Node-Positive Breast Cancer treated with sentinel Node biopsy alone after neoadjuvant chemotherapy—A rare event

Author: Barrio AV

Citation: JAMA Oncol. Published online October 07, 2021

 Factors Associated with Residual Nodal Disease among Breast Cancer patients treated with neoadjuvant chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (triple-negative) (Alliance

Author: Weiss A

Citation: SSO 2021 #Abstract 12

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute®

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 1 - Monday 10th January, 2022


Scientific Program

Session 1 : Loco-Regional therapies in breast cancer

7:15 - 7:25 pm


 **Chairpersons:** Dr. Vani Parmar, Dr. Gaurav Agarwal

 **Speaker:** Dr. Aditi Chaturvedi

 Prognosis Comparison between Nipple-Sparing Mastectomy and total Mastectomy in Breast Cancer: A case-control study after propensity score matching

Author: Fu M.


Citation: Ann Surg Oncol (2021)


 Metastasectomy versus Radiation of secondary sites in stage IV Breast Cancer: Analysis from a National cancer registry

Author: BILANI ET AL

Citation: The breast Journal., VOLUME 60, P185-191, DECEMBER 01, 2021


7:25 - 7:35 pm

 **Speaker:** Dr. Garvit Chitkara

 The incidence of Breast Cancer Recurrence 10-32 years after primary diagnosis

Author: Rikke Nørgaard Pedersen

Citation: JNCI: Journal of the National Cancer Institute, 2021

 Survival in male breast cancer (MaBC) over the past three decades

Author: LEONE ET AL

Citation: ASCO 2021 #569



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 1 - Monday 10th January, 2022


Scientific Program

Session 1 : Loco-Regional therapies in breast cancer

7:35 - 7:45 pm

 Chairpersons: Dr. Ramesh Sarin, Dr. Kapil Kumar

 Speaker: Dr. Anagha Zope

 Contemporary Multi-Institutional cohort of 550 cases of Phyllodes Tumors (2007-2017) Demonstrates a need for more individualized margin guidelines

Author: Laura H. Rosenberger, MD

Citation: J Clin Oncol. 2021 Jan 20;39(3):178-189


 Association of Risk-Reducing Salpingo-Oophorectomy with Breast Cancer risk in Women with BRCA1 and BRCA2 Pathogenic Variants

Author: Yun-Hee Choi

Citation: PhD1; JAMA Oncol. 2021;7(4):585-592


7:45 - 7:55 pm

 Speaker: Dr. Akshita Singh

 Discovery and validation of a genomic signature to identify women with early-stage invasive breast cancer who may safely omit adjuvant radiotherapy after breast-conserving surgery

Author: SJOSTROM

Citation: ASCO 2021 #512

 Long-term results of simplified lymphatic microsurgical preventing healing approach (SLYMPHA) for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection

Author: OZMEN ET AL

Citation: ASCO 2021 #514

Click on the link to register

<https://www.riveroute.in/yir2022>

Scientific Event Partner

riveroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 1 - Monday 10th January, 2022

Scientific Program


Session 1 : Loco-Regional therapies in breast cancer

7:55 - 8:10 pm

 Chairpersons: Dr. Vaishali Zamre, Dr. Nidhi Patni

Rapid Review 1

 Speaker: Dr. Nita Nair

 Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease: A Systematic Review and Meta-analysis


Author: Samiei S

Citation: JAMA Surg. 2021;156(6):e210891

 Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status. A Swedish National 6-Year Follow-up of 48 986 Women


Author: Jana de Boniface

Citation: JAMA SURGERY 2021;156(7):628-637

 A novel biosignature identifies DCIS patients with a poor biologic subtype with an unacceptably high rate of local recurrence after breast conserving surgery and radiotherapy

Author: Frank VICINI

Citation: ASCO #513

 Impact of race and ethnicity on incidence and severity of breast cancer related lymphedema after axillary lymph node dissection: Results of a prospective screening study

Author: BARRIO ET

Citation: SABCS 2021# GS4-01

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER




The year that was...2021



Day 1 - Monday 10th January, 2022




Scientific Program

Session 1 : Loco-Regional therapies in breast cancer

-  Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial
Author: Mikael Eriksson
Citation: *J Clin Oncol.* 2021 Jun 10;39(17):1899-1908
-  Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy
Author: Karoline Freeman
Citation: *BMJ* 2021;374:n1872
-  Prediction of distant relapse in patients with invasive breast cancer from deep learning models applied to digital pathology slides
Author: Ingrid Garber
Citation: *ESMO* 2021 #11240

8:10 - 8:25 pm

Rapid Review 2

-  **Speaker: Dr. Bhooshan Zade**
-  Tolerability of Breast Radiotherapy Among Carriers of ATM Germline Variants
Author: Leslie A Modlin
Citation: *JCO Precision Oncology* no. 5 (2021) 227-234
-  Comparison of Radiation with or without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In-Situ Resected by Lumpectomy: A Phase III Clinical Trial
Author: Melody A. Cobleigh
Citation: *J Clin Oncol.* 2021 Jul 20;39(21):2367-2374

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 1 - Monday 10th January, 2022

Scientific Program

Session 1 : Loco-Regional therapies in breast cancer

-  Clinicopathologic features of breast cancers diagnosed in females treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort
Author: WONG HR
Citation: ASCO 2021 #567
-  Cost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue (the DENSE trial study group)
Author: H Amarens Geuzinge
Citation: JNCI, Volume 113, Issue 11, November 2021, Pages 1476-1483
-  Estimation of Breast Cancer Overdiagnosis in US Screening Cohort
Author: RYSER ET AL
Citation: SABCS 2021 #GS4-06
-  You Get What You Pay For: Breast MRI Screening of Women With Dense Breasts Is Cost-effective.
Author: Christiane K Kuhl, MD, PhD
Citation: JNCI, Volume 113, Issue 11, November 2021, Pages 1439-1441



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 2 - Tuesday 11th January, 2022

Scientific Program


Session 2 : ER Positive Breast Cancer


6:00 - 6:10 pm

Welcome and highlights of Loco-Regional therapies in breast cancer
Dr. Shona Nag

6:10 - 6:20 pm


 **Chairpersons:** Dr. Sudha Sinha, Dr. K Pavithran

 **Speaker:** Dr. Sujay Srinivas

 Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial

Author: Ke-Da Yu


Citation: J Natl Cancer Inst.2021 Oct 1;113(10):1352-1359


 Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer.

Author: Matteo Lambertini

Citation: Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 516-516

6:20 - 6:30 pm

 **Speaker:** Dr. Mansi Sharma

 Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials

Author: Bradley R

Citation: SABCS 2021 #GS2-04

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 2 - Tuesday 11th January, 2022

Scientific Program

Session 2 : ER Positive Breast Cancer

- 📖 Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials

Author: Regan MM

Citation: SABCS 2021 #GS2-05

6:30 - 6:40 pm

👤 **Speaker: Dr. Anjana Joel**

- 📖 Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial

Author: Huma Dar

Citation: JAMA Netw Open. 2021 Jun 1;4(6):e2114904

- 📖 Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

Author: Sara M. Tolaney

Citation: J Clinical Oncol. 2021 39:24, 2720-2731

6:40 - 6:55 pm

👤 **Speaker: Dr. Ashish Bakshi**

- 📖 Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

Author: G Jerusalem

Citation: Ann Oncol.2021 Oct;32(10):1256-1266

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 2 - Tuesday 11th January, 2022

Scientific Program

Session 2 : ER Positive Breast Cancer

📖 Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

Author: Michael Gnant

Citation: N Engl J Med.2021 Jul 29;385(5):395-405

📖 Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial

Author: Lucia Del Mastro

Citation: Lancet Oncol.2021 Oct;22(10):1458-1467

6:55 - 7:05 pm

👥 **Chairpersons:** Dr. SS Alurkar, Dr. Ramesh Nimmagadda

👤 **Speaker:** Dr. Anoop TM

📖 CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)

Author: Goodwin PJ

Citation: SABCS 2021 #GS1-08

📖 UNIRAD:A UCBG randomized, double blinded, phase III international trial evaluating the addition of everolimus to adjuvant hormone therapy in women with high risk HR+ and HER2- primary breast cancer

Author: Thomas BACHELOT

Citation: ESMO Plenary

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021




Day 2 - Tuesday 11th January, 2022

Scientific Program

Session 2 : ER Positive Breast Cancer


7:05 - 7:20 pm

 **Speaker: Dr. Joydeep Ghosh**

 Characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT) and interstitial lung disease (ILD) in monarchE


Author: Masakazu Toi

Citation: Annals of Oncology (2021) 32 (suppl_2): S37-S47

 Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Author: N Harbeck

Citation: Ann Oncol. 2021 Dec;32(12):1571-1581


 Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial

Author: Gnant M

Citation: SABCS 2021 #GS1-07

7:20 - 7:35 pm

 **Speaker: Dr. Vindhya Vasini**

 Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3

Author: Massimo Cristofanilli

Citation: ASCO 2021 #1000

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 2 - Tuesday 11th January, 2022

Scientific Program

Session 2 : ER Positive Breast Cancer

- 📖 Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL

Author: M Martin

Citation: Ann Oncol. 2021 Apr;32(4):488-499

- 📖 Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study

Author: Miguel Martin Jimenez

Citation: ESMO 2021 #229MO

- 📖 Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

Author: Bidard F-C

Citation: SABCS 2021 #GS3-05

7:35 - 7:50 pm

👤 **Speaker: Dr. Rahul Kulkarni**

- 📖 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

Author: Gabriel Hortobagyi

Citation: ESMO 2021 #LBA17

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute®

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 2 - Tuesday 11th January, 2022

Scientific Program

Session 2 : ER Positive Breast Cancer

- Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

Author: Dennis J. Slamon

Citation: ASCO 2021 #1001

- Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer

Author: O'Shaughnessy J

Citation: SABCS 2021 # GS2-01

- Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

Author: Yen Shen Lu


Citation: ESMO Breast Abstract #93MO


- Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies


Author: Aleix Prat

Citation: Journal of Clinical Oncology 2021 39:13, 1458-1467

7:50 - 8:20 pm

 **Chairpersons:** Dr. Chanchal Goswami
Dr. Hemant Malhotra

-  **Keynote Talk :** "Hormone Receptor Positive Metastatic Breast Cancer: How I Treat"

 **Speaker:** Dr. Shaheenah Dawood

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER


The year that was...2021

Day 2 - Tuesday 11th January, 2022

Scientific Program


Session 2 : ER Positive Breast Cancer

8:20 - 8:35 pm

 **Chairpersons:** Dr. Harsha Panchal
Dr. Kannan Kalaichelvi


Rapid Review 1

 **Speaker:** Dr. Mansi Khanderia

 Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women


Author: Kent F. Hoskins

Citation: JAMA Oncol. 2021;7(3):370-378

 Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer


Author: Joseph A Sparano

Citation: J Clin Oncol. 2021 Feb 20;39(6):557-564

 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Author: Martine Piccart

Citation: Lancet Oncol. 2021 Apr;22(4):476-488

 Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions

Author: Joseph A. Sparano

Citation: J Clin Oncol 39:2893-2902

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 2 - Tuesday 11th January, 2022

Scientific Program

Session 2 : ER Positive Breast Cancer

- 📖 Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial.

Author: Josephine Lopes Cardozo

Citation: ASCO 2021 #Abstract 500

- 📖 Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy in the NRG Oncology/NSABP B-42 trial

Author: Rastogi P

Citation: ASCO 2021 #Abstract 502

- 📖 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

Author: Kevin Kalinsky

Citation: N Engl J Med 2021; 385:2336-2347

- 📖 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature

Author: Annelie Johansson

Citation: Annals of Oncology (2021) 32 (suppl_2): S21-S36

8:35 - 8:50 pm

Rapid Review 2

- 👤 **Speaker: Dr. Nidhi Tandon**

- 📖 Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients

Author: Gwen M H E Dackus

Citation: J Natl Cancer Inst. 2021 Nov 2;113(11):1506-1514

7th YEAR IN REVIEW BREAST CANCER






The year that was...2021



Day 2 - Tuesday 11th January, 2022

Scientific Program

Session 2 : ER Positive Breast Cancer

-  Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42
Author: Eleftherios P. Mamounas
Citation: ASCO 2021 #501
-  Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial
Author: Oleg Gluz
Citation: ASCO 2021 #504
-  Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial
Author: Ying Fan
Citation: JAMA Oncol. 2021 Oct 1;7(10):e213428
-  Stereotactic radiosurgery (SRS) for brain metastasis (BM) in hormone receptor positive (HR+) HER2 negative breast cancer (BC).
Author: Akshara Singareeka Raghavendra
Citation: ASCO 2021 #1069
-  A Risk Analysis of Alpelisib (ALP)-Induced Hyperglycemia (HG) Using Baseline Factors in Patients (pts) With Advanced Solid Tumors and Breast Cancer (BC): A Pooled Analysis of X2101 and SOLAR-1
Author: Jordi Rodon
Citation: ESMO Breast #96MO



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 2 - Tuesday 11th January, 2022

Scientific Program

Session 2 : ER Positive Breast Cancer

- 📖 A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer

Author: Yen-Shen Lu

Citation: Clin Cancer Res. 2021 Jan 15;27(2):408-417

- 📖 A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer

Author: Xu B

Citation: SABCS 2021 # GS1-06

8:50 - 9:05 pm

Rapid Review 3

- 👤 **Speaker: Dr. Krishna Prasad**

- 📖 Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer (ABC)

Author: Peter A. Fasching

Citation: ESMO Breast #2760

- 📖 Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC)

Author: Miguel Martin

Citation: ASCO 2021 #517

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 2 - Tuesday 11th January, 2022

Scientific Program

Session 2 : ER Positive Breast Cancer

- Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study

Author: S. Delaloge

Citation: ESMO Breast #630

- Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B

Author: Frederik Marmé

Citation: ASCO 2021 #518

- Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease

Author: Carsten Denkert

Citation: ASCO 2021 #519

- Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Author: Coombes C

Citation: SABCS 2021# GS3-10

- First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies

Author: Krebs MG

Citation: ESMO 2021 #230MO

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021


Day 2 - Tuesday 11th January, 2022


Scientific Program

Session 2 : ER Positive Breast Cancer

9:05 - 9:20 pm


Rapid Review 4

 **Speaker: Dr. Bhuvan Chugh**

 Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).


Author: Komal L. Jhaveri

Citation: ASCO 2021 #1017

 Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/HER2- advanced/ metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial


Author: Bardia A

Citation: SABCS 2021# GS2-02

 Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2- advanced breast cancer: Phase 1 results

Author: Marina Maglakelidze

Citation: ASCO 2021 #1063

 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study

Author: Sara Hurvitz

Citation: ESMO 2021 #LBA14

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 2 - Tuesday 11th January, 2022

Scientific Program

Session 2 : ER Positive Breast Cancer

- Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degradar, in ER-Positive, HER2-Negative Advanced Breast Cancer

Author: Aditya Bardia

Citation: J Clin Oncol. 2021 Apr 20;39(12):1360-1370

- Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis

Author: Jennifer J Gao

Citation: Lancet Oncol. 2021 Nov;22(11):1573-1581

- Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer

Author: Chandarlapaty S

Citation: SABCS 2021 #P1-17-11

9:35 pm Onwards

Closing Remarks

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 3 - Wednesday 12th January, 2022

Scientific Program

Session 3 : Her2 Positive Breast Cancer


6:30 - 6:35 pm

Highlights of Er+ve Breast Cancer and Welcome by Dr. Shona Nag

6:35 - 6:45 pm


 **Chairpersons:** Dr. Bharat Parikh, Dr. Subhash Ranjan

 **Speaker:** Dr. Chetan Deshmukh

 Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

Author: Antoinette R Tan

Citation: Lancet Oncol. 2021 Jan;22(1):85-97


 Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in theAPHINITY Trial: 6 Years' Follow-Up

Author: Martine Piccart

Citation: J ClinOncol. 2021 May 1;39(13):1448-1457


6:45 - 6:55 pm

 **Speaker:** Dr. Smitha Saldanha

 Nine weeks vs 1 year adjuvant trastuzumab: long term outcomes of the ShortHERrandomised trial

Author: CONTE ET AL

Citation: ESMO BREAST # 410

 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer

Author: H.M. Earl

Citation: ESMO 2021 #LBA11

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021




Day 3 - Wednesday 12th January, 2022

Scientific Program

Session 3 : Her2 Positive Breast Cancer


6:55 - 7:05 pm

 **Speaker: Dr. Krupa Shankar**

 Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

Author: Sara M. Tolaney


Citation: Journal of Clinical Oncology 2021 39:21, 2375-2385


 IMpassion050: A phase 3 study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy in high-risk, HER2-positive early breast cancer

Author: Jens Huober

Citation: ESMO PLENARY


7:05 - 7:15 pm

 **Speaker: Dr. Chintan Shah**

 Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

Author: Nancy U. Lin

Citation: Journal of Clinical Oncology 2021 39:24, 2667-2675

 Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.

Author: Zhongyu Yuan

Citation: ASCO 2021 #1003

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER







The year that was...2021

Day 3 - Wednesday 12th January, 2022

Scientific Program

Session 3 : Her2 Positive Breast Cancer

7:15 - 7:25 pm

-  **Chairpersons:** Dr. SVSS Prasad, Dr. Jatin Sarin
-  **Speaker:** Dr. Priya Tiwari
-  Trastuzumabderuxtecan (T-DXd) vstrastuzumabemtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
Author: CORTES J
ESMO LBA1 Annals of Oncology (2021) 32 (suppl_5): S1283-S1346.
-  Trastuzumabderuxtecanvstrastuzumabemtansine in patients with HER2+ metastatic breast cancer: Results of the randomized phase 3 study DESTINY-Breast03
Author: Hurvitz S
Citation: SABCS 2021 # GS3-01
-  Updated results of tucatinibvs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)
Author: Lin NU
Citation: SABCS 2021 PD4-04
-  Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
Author: Giuseppe Curigliano
Citation: ASCO 2021 #1043

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021




Day 3 - Wednesday 12th January, 2022

Scientific Program

Session 3 : Her2 Positive Breast Cancer


7:25 - 7:35 pm

 **Speaker: Dr. M. V. Chandrakanth**

 Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer

Author: Xu B

SABCS 2021 #GS3-02


 Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.

Author: Min Yan

Citation: ASCO 2021 #1037


7:35 - 7:45 pm

 **Speaker: Dr. Vivek Agarwala**

 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic]trastuzumabduocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer

Author: Cristina Saura Manich

Citation: ESMO 2021 # LBA15

 Datopotamabderuxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study

Author: Krop I

Citation: SABCS 2021 # GS1-05

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021


Day 3 - Wednesday 12th January, 2022


Scientific Program

Session 3 : Her2 Positive Breast Cancer

7:45 - 8:15 pm

 **Chairpersons:** Dr. Poonam Patil, Dr. Vinod Raina


 **Keynote talk :** "The HER2 Story Continues: State-of-Art in Early & Metastatic Breast Cancer"


 **Speaker:** Dr. Nadia Harbeck

8:15 - 8:30 pm

Rapid Review 1


Chairpersons: Dr. Manisha Singh, Dr. Jyoti Wadhwa

 **Speaker:** Dr. Amit Agarwal

 Biomarker analysis from KAITLIN, a randomised phase 3 study of adjuvant trastuzumabemtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC).

Author: Metzger O

Citation: ESMO BREAST #420

 Updated Results of TBCRC026: Phase II Trial Correlating | Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer

Author: Roisin M. Connolly

Citation: J ClinOncol. 2021 39:20, 2247-2256

 Evolution of HER2-low expression from primary to recurrent breast cancer

Author: Federica Miglietta

Citation: NPJ Breast Cancer. 2021 Oct 12;7(1):137.

 Pertuzumab/Trastuzumab in Early Stage HER2-positive Breast Cancer: 5-year and Final Analysis of the BERENICE Trial

Author: C. Dang

Citation: ESMO Breast #430

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 3 - Wednesday 12th January, 2022

Scientific Program

Session 3 : Her2 Positive Breast Cancer

- 📖 De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

Author: Nadia Harbeck

Citation: ASCO 2021 #503

- 📖 Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial

Author: Valentina Guarneri

Citation: EJC., VOLUME 153, P133-141, AUGUST 01, 2021

8:30 - 8:45 pm

Rapid Review 2

- 👤 **Speaker: Dr. Adwaita Gore**

- 📖 Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumabderuxtecan (T-DXd)

Author: Charles Powell

Citation: ESMO Breast #920

- 📖 Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive.

Author: Hans-Christian Kolberg

Citation: ASCO 2021 #1040

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 3 - Wednesday 12th January, 2022

Scientific Program

Session 3 : Her2 Positive Breast Cancer

- 📖 RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.

Author: Jiayu Wang

Citation: ASCO 2021 #1022

- 📖 Clinicopathological characteristics of exceptional responders who achieve durable remissions beyond five years (DR5) in HER2+(H+) metastatic breast cancer (MBC).

Author: Darko Skrobo

Citation: ASCO 2021 #1046

- 📖 Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial

Author: Nadia Harbeck

Citation: ESMO 2021 #LBA13

- 📖 Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial

Author: Jhaveri K

Citation: SABCS 2021 #GS4-10

8:45 pm onwards

Vote of thanks



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 4 - Thursday 13th January, 2022

Scientific Program


Session 4 : Triple Negative Breast Cancer


6:30 - 6:40 pm

Welcome and highlights of HER2+ve Session
Dr. Shona Nag

6:40 - 6:55 pm


 **Chairpersons:** Dr. Sanjay Sharma, Dr. Sadashivudu Gundeti

 **Speaker:** Dr. Vijay Agarwal

 Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC


Author: Peter Schmid

Citation: ESMO VIRTUAL PLENARY

 KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses


Author: Schmid P

Citation: SABCS 2021 # GS1-01

 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

Author: Hope Rugo

Citation: ESMO 2021 #LBA16

 Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Author: Cortes J

Citation: SABCS 2021 # GS1-02

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021





Day 4 - Thursday 13th January, 2022

Scientific Program

Session 4 : Triple Negative Breast Cancer


6:55 - 7:05 pm

 **Speaker: Dr. Randeep Singh**

 Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Author: Eric P Winer


Citation: Lancet Oncol. 2021 Apr;22(4):499-511


 Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial

Author: Amy Jo Chien

Citation: ASCO 2021 # 508


7:05 - 7:15 pm

 **Speaker: Dr. Ashish Singh**

 Atezolizumab with carboplatin as immune induction in metastatic lobular breast cancer: first results of the GELATO-trial

Author: Leonie Voorwerk

Citation: ESMO BREAST # LBA 310

 Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neoadjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)

Author: Sibylle Loibl

Citation: ASCO 2021 #506

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021





Day 4 - Thursday 13th January, 2022

Scientific Program

Session 4 : Triple Negative Breast Cancer


7:15 - 7:25 pm

 **Speaker: Dr. Sushmita Rath**

 OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer

Author: Andrew Tutt


Citation: ASCO 2021 #LBA 1


 Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer


Author: Ganz PA

Citation: SABCS 2021 # GS4-09

7:25 - 7:35 pm


 **Chairpersons: Dr. Maheboob Basade, Dr. P N Mohapatra**

 **Speaker: Dr. M Vamshi Krishna**

 Characterization of long-term responders following treatment with talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 embraca trial

Author: Johannes Ettl

Citation: ASCO 2021 #1029

 Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥ 4 years of follow-up: BrighTNess, a randomized phase III trial

Author: Sibylle Loibl

Citation: ESMO 2021 #1190

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER






The year that was...2021

Day 4 - Thursday 13th January, 2022



Scientific Program

Session 4 : Triple Negative Breast Cancer

7:35 - 7:50 pm

-  **Speaker: Dr. Satya Dattatreya**
-  **Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer**
Author: Aditya Bardia
Citation: N Engl J Med 2021; 384:1529-1541
-  **Outcomes in patients (pts) aged ≥ 65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)**
Author: Kevin Kalinsky
Citation: ASCO 2021 #1011
-  **Assessment of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).**
Author: Joyce O'Shaughnessy
Citation: ASCO 2021 #1077
-  **Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).**
Author: Lisa A. Carey
Citation: ASCO 2021 #1080

7:50 - 8:00 pm

-  **Speaker: Dr. Suman Karanth**
-  **Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US**
Author: Elizabeth B Elimimian
Citation: JAMA Netw Open.2021 Apr 1;4(4):e214123

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 4 - Thursday 13th January, 2022

Scientific Program

Session 4 : Triple Negative Breast Cancer

- 📖 Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls

Author: Frederic Amant

Citation: ASCO 2021 #515

8:00 - 8:10 pm

👤 **Speaker: Dr. Seema Gulia**

- 📖 Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

Author: Ingrid A. Mayer

Citation: Journal of Clinical Oncology 2021 39:23, 2539-2551

- 📖 Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study

Author: Sudeep Gupta

Citation: Breast. 2021 Dec;60:147-154

8:10 - 8:25 pm

Chairpersons: Dr. Govind Babu, Dr. G S Chowdhary

Rapid Review 1

👤 **Speaker: Dr. Bharath Rangarajan**

- 📖 Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions

Author: Olivia M. Lansinger

Citation: Journal of Clinical Oncology 2021 39:32, 3583-3590

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER







The year that was...2021



Day 4 - Thursday 13th January, 2022

Scientific Program

Session 4 : Triple Negative Breast Cancer

-  Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis
Author: Jennifer A Crozier
Citation: LANCET ONCOLOGY 2020 Dec;21(12):1611-1619
-  Association of statin use with clinical outcomes in patients with triple-negative breast cancer
Author: Malgorzata K
Citation: CANCER Volume127, Issue22 November 15, 2021 Pages 4142-4150
-  Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).
Author: Amit Bahl
Citation: ASCO 2021 #1008
-  Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials
Author: Braybrooke J
Citation: SABCS 2021 # GS2-06
-  Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase 1 trial
Author: Aditya Bardia
Citation: ESMO Breast # LBA4
-  Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study
Author: Jennifer Keating Litton
Citation: ASCO 2021 #505

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021


Day 4 - Thursday 13th January, 2022


Scientific Program

Session 4 : Triple Negative Breast Cancer

8:25 - 8:40 pm


Rapid Review 2

 **Speaker: Dr. Amit Rauthan**

 Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study


Author: Li Chen

Citation: ASCO 2021 #1007

 BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd)


Author: Peter Schmid

Citation: ASCO 2021 #1023

 Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).

Author: Priyanka Sharma

Citation: ASCO 2021 #1076

 Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844)

Author: Evanthia Roussos Torres

Citation: ESMO 2021 #964MO

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 4 - Thursday 13th January, 2022

Scientific Program

Session 4 : Triple Negative Breast Cancer

- 📖 **Nimbus:** A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)

Author: Barroso-Sousa R

Citation: SABCS 2021 # GS2-10

- 📖 **BARBICAN:** A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer

Author: Peter Schmid

Citation: ESMO 2021 #123MO



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 5 - Friday 14th January, 2022

Scientific Program

Session 5 : Supportive Care in Breast Cancer

6:00 - 6:10 pm


Highlights of TNBC and Welcome address Dr. Shona Nag

6:10 - 6:50 pm

 Chairpersons: Dr. Avinash Deo, Dr. Kiran Kattimani


6:10 - 6:20 pm

 Speaker: Dr. Priyanka Srivastava

 Development and Validation of a Risk Model for Breast Cancer-Related Lymphedema Jennifer

Author: Yin Yee Kwan

Citation: JAMA Netw Open. 2020 Nov 2;3(11):e2024373.


 Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer

Author: Allison Magnuson

Citation: J Clin Oncol. 2021 Feb 20;39(6):608-618.


6:20 - 6:30 pm

 Speaker: Dr. Joy Ghose

 Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): multicentre randomised controlled trial and economic evaluation

Author: Julie Bruce

Citation: BMJ. 2021 Nov 10;375: e066542.

 Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis

Author: Ana Elisa Lohmann

Citation: J Natl Cancer Inst. 2021 Nov 2;113(11):1465-1475.

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 5 - Friday 14th January, 2022

Scientific Program

Session 5 : Supportive Care in Breast Cancer


6:30 - 6:40 pm

 **Speaker: Dr. Rakesh Pinninti**

 Sugar-Sweetened Soda Consumption and Total and Breast Cancer Mortality: The Western New York Exposures and Breast Cancer (WEB) Study

Author: Nadia Koyratty

Citation: Cancer Epidemiol Biomarkers Prev . 2021 May;30(5):945-952.

 A Coala-T-Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment

Author: Marisa C Weiss

Citation: Cancer. 2022 Jan 1;128(1):160-168.

6:40 - 6:50 pm

 **Speaker: Dr. Amol Dongre**

 Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.

Author: Evandro de Azambuja

Citation: Journal of Clinical Oncology 2021 39:15_suppl, 510-510

 Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer

Author: Naruto Taira

Citation: J Clin Oncol. 2021 Aug 1;39(22):2452-2462.

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021








Day 5 - Friday 14th January, 2022




Scientific Program

Session 5 : Supportive Care in breast cancer

6:50 - 7:05 pm

-  **Chairpersons:** Dr. Raghunadharao D, Dr. Nikhilesh Borkar
-  **Speaker:** Dr. Veda Padma Priya
-  **Risk of Late-Onset Breast Cancer in Genetically Predisposed Women**
Author: Nicholas J Boddicker
Citation: *J Clin Oncol.* 2021 Nov 1;39(31):3430-3440.
-  **Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial**
Author: Miranda P Steenbeek
Citation: *JAMA Oncol.* 2021 Aug 1;7(8):1203-1212.
-  **Use of a high-sensitivity anti-Mullerian hormone (AMH) assay to determine ovarian function after chemotherapy for early breast cancer.**
Author: Florian Clatot
Citation: *Journal of Clinical Oncology* 2021 39:15_suppl, 552-552

7:05 - 7:15 pm

-  **Speaker:** Dr. Shruti Kate
-  **Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis**
Author: Matteo Lambertini
Citation: *J Clin Oncol.* 2021 Oct 10;39(29):3293-3305.
-  **Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data**
Author: Volkan Turan
Citation: *J Clin Oncol.* 2021 Jun 20;39(18):2016-2024.

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021





Day 5 - Friday 14th January, 2022

Scientific Program

Session 5 : Supportive Care in breast cancer


7:15 - 7:30 pm

 **Speaker: Dr. Bhawna Sirohi**

 Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors


Author: Tal Sella

Citation: Cancer. 2021 Aug 15;127(16):2888-2894.

 Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, HER 2-Negative Advanced Breast Cancer From SOLAR-1


Author: Eva Maria Ciruelos

Citation: J Clin Oncol. 2021 Jun 20;39(18):2005-2015.

 Real-world comparison of febrile neutropenia rates with same-day versus next-day administration of pegfilgrastim.


Author: Kyle Kitchen

Citation: Journal of Clinical Oncology 2021 39:28_suppl, 299-299

 122MO - Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without Palbociclib

Author: José García-Saenz

*Citation: Annals of Oncology (2021) 32 (suppl_5): S407-S446.
10.1016/annonc/annonc687*

 440 - Characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT) and interstitial lung disease (ILD) in monarchE

Author: Masakazu Toi

*Citation: Annals of Oncology (2021) 32 (suppl_2): S37-S47.
10.1016/annonc/annonc504*

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 5 - Friday 14th January, 2022

Scientific Program

Session 5 : Supportive Care in breast cancer

- 📖 920 - Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)

Author: Charles Powell

*Citation: Annals of Oncology (2021) 32 (suppl_2): S60-S78.
10.1016/annonc/annonc508*

- 📖 Lisinopril or carvedilol in prevention of trastuzumab-induced cardiotoxicity in patients with HER2-positive early stage breast cancer: Longitudinal changes of left ventricular ejection fraction below normal levels (LVEF <50%)

Author: Pamela N. Munster

Citation: Journal of Clinical Oncology 2021 39:15_suppl, 509-509

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021




Day 5 - Friday 14th January, 2022


Scientific Program

Session 6 : Translational Science in breast cancer

7:30 - 7:40 pm


 **Chairpersons:** Dr. Shalaka Joshi, Dr. Subrata Sinha

 **Speaker:** Dr. Peush Bajpai

 A Population-Based Study of Genes Previously Implicated in Breast Cancer

Author: Chunling Hu

Citation: N Engl J Med 2021; 384:440-451


 Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis

Author: Peter A. Fasching

Citation: J Clin Oncol.2021 May 20;39(15):1619-1630


7:40 - 7:50 pm

 **Speaker:** Dr. Kripa Bajaj

 Detection of homologous recombination repair deficiency (HRD) in treatment-naïve early triple-negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests

Author: V. Serra Elizalde

Citation: ESMO Breast #10

 Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

Author: Llop-Guevara A

Citation: ESMO Breast #20

Click on the link to register

<https://www.riveroute.in/yir2022>

Scientific Event Partner

riveroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 5 - Friday 14th January, 2022

Scientific Program

Session 6 : Translational Science in breast cancer

7:50 - 8:05 pm

 **Speaker: Dr. Moushumi Suryavanshi**

 Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score


Author: Chi Gao

Citation: J Clin Oncol.2021 Aug 10;39(23):2564-2573

 Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast

Author: Siddhartha Yadav

Citation: J Clin Oncol.2021 Dec 10;39(35):3918-3926


 Association Between Hereditary Lobular Breast Cancer Due to CDH1 Variants and Gastric Cancer Risk

Author: Lauren A Gamble

Citation: JAMA Surg. 2021 Oct 13;e215118


8:05 - 8:15 pm

 **Speaker: Dr. Abhenil Mittal**

 Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center

Author: Abhenil Mittal

Citation: Ann Surg Oncol.2021 Oct 2;1-10

 Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Author: Nindo B. Punturi

Citation: Nat Commun 12, 2940 (2021)

Click on the link to register

<https://www.riveroute.in/yir2022>

Scientific Event Partner

riveroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 5 - Friday 14th January, 2022


Scientific Program

Session 6 : Translational Science in breast cancer

8:15 - 8:25 pm


 **Chairpersons:** Dr. Atul Sharma, Dr. Thangarajan Rajkumar

 **Speaker:** Dr. Nirmal Raut

 Clinical utility of molecular tumor profiling: results from the randomized trial SAFIRO2-BREAST

Author: André F

Citation: SABCS 2021 # GS1-10


 Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project

Author: D M Vega

Citation: Ann Oncol. 2021 Dec;32(12):1626-1636


8:25 - 8:35 pm

 **Speaker:** Dr. Deepam Pushpam

 Genomic analysis of 733 HER2+ breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities

Author: Ferraro E

Citation: SABCS 2021 # GS3-03

 Cycling cancer persister cells arise from lineages with distinct programs

Author: Oren Y

Citation: Nature 596, 576-582 (2021)

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 5 - Friday 14th January, 2022


Scientific Program

Session 6 : Translational Science in breast cancer

8:35 - 8:50 pm


Rapid Review 1

 **Speaker: Dr. Rohit Pai**

 Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study


Author: Ajjai S Alva

Citation: J Clin Onco . 2021 Aug 1;39(22):2443-2451

 Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases


Author: Prakadan, S.M.

Citation: Nat Commun 12, 5955 (2021)

 Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis


Author: Priscilla K Brastianos

Citation: Nat Commun.2021 Oct 12;12(1):5954

 GS1-00 Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial

Author: Bianchini G

Citation: SABCS 2021

 Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD

Author: D Hodgson

Citation: Ann Oncol.2021 Dec;32(12):1582-1589

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 5 - Friday 14th January, 2022

Scientific Program

Session 6 : Translational Science in breast cancer

- 📖 PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later

Author: J Fuentes-Antrás

Citation: Ann Oncol.2021 Dec;32(12):1460-1462

- 📖 Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial

Author: Joseph A. Sparano

Citation: ASCO 2021 # 520

- 📖 The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).

Author: Nour Abuhadra

Citation: ASCO 2021 # 590

- 📖 MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors

Author: Funda Meric-Bernstam

Citation: ASCO 2021 # 3004

8:50 - 9:05 pm

Rapid Review 2

- 👤 **Speaker:** Dr. Shona Nag

- 📖 Plasma cell-free DNA integrity predicts the achievement of pathological complete response to neoadjuvant chemotherapy in breast cancer patients

Author: Cirmena G

Citation: AACR 2021 #LB063

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER






The year that was...2021



Day 5 - Friday 14th January, 2022

Scientific Program

Session 6 : Translational Science in breast cancer

-  Usefulness of assessment of circulating tumor DNA(ctDNA) of cerebrospinal fluid(CSF) samples for early detection of brain metastasis (BrM) in patients with triple-negative breast cancer (TNBC).
Author: Lucrezia Raimondi
Citation: ASCO 2021 #507
-  Serial circulating tumor DNA samples from patients with metastatic breast cancer and BRCA1/2 mutations
Author: Katharine Collier
Citation: ASCO 2021 #1025
-  Primary results of the cTRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer
Author: Turner N
Citation: SABCS 2021 # GS3-06
-  Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioltaLEE trial
Author: Bianchini G
Citation: SABCS 2021 # GS3-07
-  Dual-mechanism estrogen receptor inhibitors
Author: Jian Min
Citation: Proc Natl Acad Sci U S A 2021 Aug 31;118(35):e2101657118






7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 5 - Friday 14th January, 2022

Scientific Program

Session 6 : Translational Science in breast cancer

-  Prospective longitudinal multi-omics study of palbociclib resistance in hormone receptor+/HER2- metastatic breast cancer
Author: Yeon Hee Park
Citation: ASCO 2021 #1013
-  CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study
Author: Javier Pascual
Citation: ASCO 2021 # 1014
-  Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations
Author: Kubler K, Nardone A
Citation: SABCS 2021 # GS2-09

9:05 pm Onwards

Vote of thanks



7th YEAR IN REVIEW BREAST CANCER

The year that was...2021

Day 6 - Saturday 15th January, 2022

Scientific Program

Keynote Presentations and Panel Discussions

4:00 - 4:05 pm

Welcome Address
Dr. Sudeep Gupta

Session 7 : Locoregional Breast Cancer

 Chairpersons: Dr. Budhi Singh Yadav, Dr. Tejinder Kataria

4:05 - 4:50 pm

 Panel Discussion on key abstracts in Loco Regional Breast Cancer

 Moderator: Dr. K Geeta

Panelists: Dr. Kanchan Kaur, Dr. Anupama Mane,
Dr. Deepak Jha, Dr. Gautam Sharan,
Dr. Vedant Kabra, Dr. Sidharth Sahni
Dr. Prasanjit Chatterjee, Dr. Sanjoy Chatterjee,
Dr. Vikram Maiya, Dr. Monica Malik

Session 8 : ER+ve Breast Cancer

 Chairpersons: Dr. Shekar Patil, Dr. Ravi Mohan

4:50 - 5:20 pm

 Genomic Testing in Clinical Decisions: Hormone Receptor
Positive EBC

 Speaker: Dr. Lee Soo Chin

Click on the link to register

<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

Leaders in Streaming Modules

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



Day 6 - Saturday 15th January, 2022

Scientific Program

Keynote Presentations and Panel Discussions



5:20 - 6:05 pm

-  Chairpersons: TBA,
Dr. D C Doval
-  Panel Discussion on key abstracts in ER+ve Breast Cancer
-  Moderator: Dr. Senthil Rajappa
- Panelists: Dr. TVSVGK Tilak, Dr. Ghanshyam Biswas,
Dr. Amish Vora, Dr. Shyam Aggarwal,
Dr. Gautam Goyal, Dr. Nirav Asarawala,
Dr. Sandeep Goyle, Dr. Reetu Jain,
Dr. Partha Roy



Session 9 : HER2+ve Breast Cancer

Chairpersons: Dr. Anand Pathak,
Dr. N. K. Warriar

6:05 - 6:35 pm

-  "Treatment of Metastatic Breast Cancer: A Full Cupboard Waiting to be Opened"
-  Speaker: Dr. Giuseppe Curigliano

6:35 - 7:20 pm

-  Chairpersons: Dr. Shailesh Bondarde, Dr. Harsh Dua
-  Panel discussion on key abstracts in HER2+ve breast Cancer
- Moderator: Dr. Prasad Narayanan
- Panelists: Dr. A K Vaid, Dr. Anubha Bhartuar,
Dr. Abhishek Kakroo, Dr. Manish Kumar,
Dr. Sachin Hingmire, Dr. T P Sahoo,
Dr. Chirag Desai, Dr. Amit Dutt Dwary,
Dr. Arun Warriar, Dr. Rejiv Rajendranath



7th YEAR IN REVIEW BREAST CANCER




The year that was...2021

Day 6 - Saturday 15th January, 2022




Scientific Program

Keynote Presentations and Panel Discussions

7:20 - 7:50 pm

-  Chairpersons: Dr. S H Advani, Dr. D Loknath
-  "Treatment of Early and Metastatic Triple Negative Breast Cancer: Now and Next Few Years"
-  Speaker: Dr. Aditya Bardia

7:50 - 8:35 pm

-  Chairpersons: Dr. Meenu Walia, Dr. Rajiv Sarin
-  Panel discussion on key publications in TNBC
-  Moderator: Dr. Nitish Rohatgi
- Panelists: Dr. B K Smruti, Dr. Anita Ramesh, Dr. Vashistha Maniar, Dr. Amol Patel, Dr. Muzzamil Shaikh, Dr. Sandeep Batra, Dr. Jyoti Bajpai, Dr. Biswajit Dubashi, Dr. Bharat Vaswani, Dr. Niti Raizada

8:35 - 8:55 pm

-  Chairpersons: Dr. S. D. Banavali, Dr. Tapan Saikia
-  Did you know ?
-  Speaker: Dr. Sudeep Gupta

8:55 pm Onwards

Vote of thanks

7th YEAR IN REVIEW BREAST CANCER

The year that was...2021



10th - 15th JAN 2022

Virtual Event Managed By

riverroute[®]

■ Leaders in Streaming Modules

Rekha Ghorpade

Webinar Manager,
River Route Event, Mumbai

Mobile: +91 8082764779 | E-mail : rrcg.rekha@gmail.com



Click on the link to register
www.yearinreview.in/yir2022

Click on the link to register
<https://www.riverroute.in/yir2022>

Scientific Event Partner

riverroute[®]

■ Leaders in Streaming Modules